Numerous studies have shown that cloricromene, a semi-synthetic non-anticoagulant coumarin derivative, exerts a clear protective action in several experimental models of ischaemia and shock (1). The antithrombotic and anti-ischemic effects of cloricromene are evident in the peripheral ischemia for the difficult of the drug to pass the brain-blood barrier (BBB). Recently, polymeric nanoparticles have been proposed as interesting alternative to the traditional approaches to overcome brain drug delivery obstacles (2). Among the techniques proposed in the preparation of nanoparticles from polyester polymers, such as poly (D,L lactide) (PLA) or poly (D,L lactide-co-glicolide) (PLGA), the nanoprecipitation method (3) represents an easy and reproducible technique to obtain nanoparticles below 200 nm. However, this method is basically applicable to lipophilic drugs and several attempts are developed in order to improve hydrophilic drug encapsulation. Cloricromene is rapidly metabolised in vitro or in vivo in the blood into a stable and active catabolite (Cloricromene acid, AD6-acid) through the hydrolysis of an ester bound within the molecule (Fig 1). Cloricromene (as chloride salt, AD6) is freely soluble in water even if it is very lipophilic (log P= 3.96); on the contrary the catabolite is poorly soluble in water and is less lipophilic than Cloricromene (log P = 3.12). The aim of this paper was to evaluate which of the two drug forms has more possibility to be encapsulated efficiently in the nanoparticles, according to the parameters used in the preparation.

Preparation and characterization of biodegradable nanoparticles containing a lipophilic drug in water-soluble or insoluble form / Leo, Eliana Grazia; Brina, Barbara; Ruozi, Barbara; Vandelli, Maria Angela; Forni, Flavio. - In: FARMACEVTSKI VESTNIK. - ISSN 0014-8229. - STAMPA. - 54 (SPEC. ISS.):(2003), pp. 391-392. (Intervento presentato al convegno Farmacevtski Vestnik, 5° Central European Symposium on Pharmaceutical Technology and Biotechnology tenutosi a Lubiana nel 26-29 Settembre 2003).

Preparation and characterization of biodegradable nanoparticles containing a lipophilic drug in water-soluble or insoluble form

LEO, Eliana Grazia;BRINA, Barbara;RUOZI, Barbara;VANDELLI, Maria Angela;FORNI, Flavio
2003

Abstract

Numerous studies have shown that cloricromene, a semi-synthetic non-anticoagulant coumarin derivative, exerts a clear protective action in several experimental models of ischaemia and shock (1). The antithrombotic and anti-ischemic effects of cloricromene are evident in the peripheral ischemia for the difficult of the drug to pass the brain-blood barrier (BBB). Recently, polymeric nanoparticles have been proposed as interesting alternative to the traditional approaches to overcome brain drug delivery obstacles (2). Among the techniques proposed in the preparation of nanoparticles from polyester polymers, such as poly (D,L lactide) (PLA) or poly (D,L lactide-co-glicolide) (PLGA), the nanoprecipitation method (3) represents an easy and reproducible technique to obtain nanoparticles below 200 nm. However, this method is basically applicable to lipophilic drugs and several attempts are developed in order to improve hydrophilic drug encapsulation. Cloricromene is rapidly metabolised in vitro or in vivo in the blood into a stable and active catabolite (Cloricromene acid, AD6-acid) through the hydrolysis of an ester bound within the molecule (Fig 1). Cloricromene (as chloride salt, AD6) is freely soluble in water even if it is very lipophilic (log P= 3.96); on the contrary the catabolite is poorly soluble in water and is less lipophilic than Cloricromene (log P = 3.12). The aim of this paper was to evaluate which of the two drug forms has more possibility to be encapsulated efficiently in the nanoparticles, according to the parameters used in the preparation.
2003
54 (SPEC. ISS.)
391
392
Leo, Eliana Grazia; Brina, Barbara; Ruozi, Barbara; Vandelli, Maria Angela; Forni, Flavio
Preparation and characterization of biodegradable nanoparticles containing a lipophilic drug in water-soluble or insoluble form / Leo, Eliana Grazia; Brina, Barbara; Ruozi, Barbara; Vandelli, Maria Angela; Forni, Flavio. - In: FARMACEVTSKI VESTNIK. - ISSN 0014-8229. - STAMPA. - 54 (SPEC. ISS.):(2003), pp. 391-392. (Intervento presentato al convegno Farmacevtski Vestnik, 5° Central European Symposium on Pharmaceutical Technology and Biotechnology tenutosi a Lubiana nel 26-29 Settembre 2003).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/465451
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact